Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 94   

Articles published

ALKS 43.22 -0.27 (-0.62%)
price chart
Q2 2016 Earnings Estimate for Alkermes Plc Issued By Leerink Swann (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) - Investment analysts at Leerink Swann lifted their Q2 2016 earnings per share estimates for Alkermes Plc in a research report issued on Tuesday. Leerink Swann analyst P. Matteis now expects that the firm ...
Analyst Rating Update on Alkermes plc (ALKS)
Alkermes plc (NASDAQ:ALKS) : The consensus on Alkermes plc (NASDAQ:ALKS) based on 5 analyst recommendation on the company stock is 1.66, which is interpreted as a Buy recommendation.
Alkermes plc (NASDAQ:ALKS) Received An ABR Of 1.66
Alkermes plc (NASDAQ:ALKS) continues to hold a positive outlook, from sell-side analysts. As is evident by a recent poll conducted by Zacks Research, the company's stock has received an ABR of 1.66.
Alkermes Plc's (ALKS) "Outperform" Rating Reaffirmed at Leerink Swann
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS)'s stock had its “outperform” rating reaffirmed by stock analysts at Leerink Swann in a research note issued to investors on Tuesday.
Alkermes Plc (ALKS) Ascent Sends Options Volume to the Moon
A number of drug stocks are making moves higher, and biotech Alkermes Plc (NASDAQ:ALKS) is no exception amid unsubstantiated takeover talk.
Alkermes plc (NASDAQ:ALKS) Closes At $42.98  Vanguard Tribune
Take a look at Analysts Tips: Cigna Corporation (NYSE:CI) , Alkermes plc ...  Street Updates
Alkermes plc (NASDAQ:ALKS) earnings expectations
Alkermes plc (NASDAQ:ALKS) is expected to announce second quarter financial results estimated on July 28, 2016. The company added about 6.1 percent in value since last earnings when it was at $40.57.
Price Target Update on Alkermes plc (NASDAQ:ALKS)  Trade Calls
Alkermes Plc (NASDAQ:ALKS) Updated Price Targets  FTSE News
Alkermes plc (NASDAQ:ALKS) Moderate Sell Ratings At 0
Alkermes plc (NASDAQ:ALKS) strong sell score is 0 while buy rating count is 0. Moderate sell ratings are 0 while moderate buy calls are 4. Hold ratings count is 2. As many as 1 brokerages initiated coverage on Alkermes plc (NASDAQ:ALKS) while 4 ...
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and ...
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Alkermes Plc (ALKS) Richard F. Pops on Q4 2015 Results - Earnings Call ...  Seeking Alpha
Alkermes Q4 Loss Narrower than Expected, Updates Pipeline
Alkermes plc (NASDAQ:ALKS) Yearly EBIT At $-224.301 Millions
For the fiscal ended 2015-12-31, Alkermes plc (NASDAQ:ALKS) comprehensive income was $-3.795 millions. The number, for the quarter closed 2015-12-31 was $-3.795 millions.
Alkermes plc (ALKS) Commences ALKS 4230 Phase 1
Alkermes plc (Nasdaq: ALKS) announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA™) protein designed for ...
Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ...  Benzinga